Reuters logo
BRIEF-New preclinical data further strengthen rationale of IPH5401 and Monalizumab
September 11, 2017 / 5:27 AM / 10 days ago

BRIEF-New preclinical data further strengthen rationale of IPH5401 and Monalizumab

Sept 11 (Reuters) - INNATE PHARMA SA:

* REG-INNATE PHARMA : NEW PRECLINICAL DATA FURTHER STRENGTHEN THE RATIONALE OF IPH5401 AND MONALIZUMAB

* ‍IPH5401 POTENTIALLY REVERSES TUMOR IMMUNO-SUPPRESSIVE MICROENVIRONMENT AND OVERCOMES TUMOR RESISTANCE​

* ‍PRECLINICAL DATA SUGGEST THAT COMBINED C5AR AND PD-1 BLOCKADE SYNERGISTICALLY REDUCE TUMOR GROWTH​

* ‍NEW PRECLINICAL DATA FURTHER REINFORCE RATIONALE FOR COMBINATION TREATMENT WITH MONALIZUMAB (ANTI-NKG2A) AND ANTI-PD-L1 CHECKPOINT INHIBITORS​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below